V-ATPase C Inhibitors

Chemical inhibitors of V-ATPase C function by interfering with the enzyme's ability to establish and maintain a proton gradient across cellular membranes, which is essential for its role in acidifying various intracellular compartments. Bafilomycin A1 and Concanamycin A achieve this by binding to the subunit c of the V0 domain of V-ATPase C, directly preventing proton translocation. Similarly, Saliphenylhalamide targets the V0 sector, blocking the enzyme's activity and disrupting the proton gradient formation. Oxiconazole, though primarily known for its antifungal properties, also hinders V-ATPase C by interfering with the enzyme's proton pump mechanism.

In addition to these direct inhibitors, other compounds affect V-ATPase C indirectly by altering the enzyme's operating environment. Indole-3-carbinol can change cellular pH levels, which in turn can affect the proton gradient necessary for V-ATPase C function. Pidotimod, while modulating immune responses, can affect the endosomal-lysosomal pathway acidification, potentially altering the enzyme's activity. Lys05, as a lysosomal autophagy inhibitor, disrupts lysosomal acidification, which is dependent on the proton pump activity of V-ATPase C. Desmethylclomipramine inhibits the acidification of intracellular compartments, thus impeding the function of V-ATPase C by changing the essential proton gradient. Chloroquine raises the pH of intracellular compartments such as lysosomes and endosomes, which would inhibit the V-ATPase C by altering its operating environment. Lastly, Niclosamide, by uncoupling proton gradients across membranes, disrupts the proton gradient needed for V-ATPase C's acidification activity.